secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0000950170-24-085044
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent doses first patient in Phase 1 trial of HER2-selective inhibitor NVL-330 for NSCLC
--------------------------------------------------------------------------------

- Initiated HEROEX-1 Phase 1a/1b trial evaluating NVL-330 in pre-treated patients with HER2-altered NSCLC.
- First patient dosed on July 22, 2024; trial will assess safety, tolerability, PK, and preliminary anti-tumor activity.
- Trial objectives include determination of recommended Phase 2 dose (RP2D) for NVL-330.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024085044/0000950170-24-085044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024085044/nuvl-20240722.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-085044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer